Daniel P. Petrylak, MD, presented “Anti-Androgen Trials” during the 30th Annual International Prostate Cancer Update on January 23rd, 2020 in Beaver Creek, Colorado.
How to cite: Petrylak, Daniel P. “Anti-Androgen Trials” January 23rd, 2020. Accessed May 2021. https://dev.grandroundsinurology.com/anti-androgen-trials/
Anti-Androgen Trials – Summary:
Daniel P. Petrylak, MD, Director of Genitourinary Oncology, Professor of Medicine and Urology, Co-Leader of Cancer Signaling Networks, and Co-Director of the Signal Transduction Program at Yale University Cancer Center, gives an overview of the most important, recent anti-androgen trials, as well as those that are currently still underway. He highlights how the trials were conducted, what the researchers found, and what he feels is still missing from the research. Dr. Petrylak compares and contrasts the different studies and draws conclusions about each. He also goes over a couple of trials with novel anti-androgens with unique mechanisms of action, which are currently in phase 1, that are showing promise.
About The 30th Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. Dr. Petrylak gave this presentation during the 30th iteration of the meeting in January 2020.
For further educational activities from this conference, visit our collection page.